Conditions: Tumors
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 16
Healthy volunteers: no

Brief summary:
This is a clinical study to evaluate the safety and pharmacokinetics of an overseas determined maximum tolerated dose (MTD) of MK-0683 (vorinostat) in a Japanese patient population with solid tumors.

Detailed description:

Arms:
arm 1: 600 mg daily (300 mg twice daily \[b.i.d.\]) for 3 consecutive days followed by 4 days of rest. arm 2: 400 mg once daily (400 mg q.d.) continuous daily dosing for 21 days.

Interventions: intervention 1: Vorinostat intervention 2: Vorinostat
Intervention descriptions: intervention 1: 600 mg daily (300 mg twice daily \[b.i.d.\]) for 3 consecutive days followed by 4 days of rest. intervention 2: 400 mg once daily (400 mg q.d.) continuous daily dosing for 21 days.

Protocol document: